Abstract:Background The outcome of intermediate-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) is greatly heterogeneous. Current means for predicting HCC response to TACE are lacking. Purpose To investigate whether the combination of parameters derived from amide proton transfer (APT) and intravoxel incoherent motion (IVIM) imaging, and morphological characteristics of tumor can establish a better prediction model than the univariant model for HCC response to TACE. Study Type Prospective. Subjects 56 patients with intermediate-stage HCC (50 males and six females). Field Strength/Sequences 3.0T; T-2-weighted-fast spin echo, 3D liver acquisition with volume flex, single-shot fast spin echo-planar imaging (EPI), spin echo-EPI. Assessment Pretreatment APT signal intensities (SIs), apparent diffusion coefficient (ADC), true molecular diffusion coefficient (D), pseudodiffusion coefficient (D*), and perfusion fraction (f) for tumor, peritumoral, and normal tissues were measured. Follow-up MRI scanning was performed, and the patients were classified as responders or nonresponders based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Statistical Tests The imaging parameters were compared among the three tissues and between the two groups using analysis of variance (ANOVA) or two-sample t-test. The prediction model's variables were derived from univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve analysis was used to explore the predictive performance. Results Based on the logistic regression analysis results, we established a prediction model that integrated the APT SI and D values in the tumor tissue and the tumor size. ROC analyses revealed that the model was better able to predict tumor response to TACE (area under the ROC curve = 0.851) than the individual parameters on their own. Data Conclusion A prediction model incorporating pretreatment APT SI, D in the tumor tissue and tumor size may be useful for predicting the response of intermediate-stage HCC to TACE. Level of Evidence 1 Technical Efficacy Stage 1

A New Prediction Model for Prognosis of Patients with Intermediate HCC after Conventional Transarterial Chemoembolization.

A New Prediction Model for Prognosis of Patients with Intermediate-Stage HCC after Conventional Transarterial Chemoembolization: an Internally Validated Study.

A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma

Evaluating the Predictive Power of Circulating Tumor Cells for the Prognosis of Transarterial Chemoembolization Treatment on Patients with Advanced Hepatocellular Carcinoma

Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization

Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors

Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.

Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization

Prediction Model of No-Response Before the First Transarterial Chemoembolization for Hepatocellular Carcinoma: TACF Score

Novel Prognostic Nomogram to Predict Progression-Free Survival of Patients with Hepatocellular Carcinoma After Transarterial Chemoembolization

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study.

Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma

Development and Validation of a Deep Learning Model for Survival Prognosis of Transcatheter Arterial Chemoembolization in Patients with Intermediate-Stage Hepatocellular Carcinoma

Prediction of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization: A Real-World Study Based on Non-Contrast Computed Tomography Radiomics and General Image Features

Factors to Transcatheter Arterial Chemoembolization Liver Cancer Stage C

Nomogram predicting the prognosis of primary liver cancer after radiofrequency ablation combined with transcatheter arterial chemoembolization

An Interpretable Machine Learning Model Based on Contrast-Enhanced CT Parameters for Predicting Treatment Response to Conventional Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.

Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients With Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients

A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma